Gregory L. Weaver net worth and biography

Gregory Weaver Biography and Net Worth

Gregory L. Weaver serves as Independent Director of the Company. Mr. Weaver served as Chief Financial Officer of Eloxx Pharmaceuticals, Inc. (Nasdaq: ELOX) a publicly traded biotech company from September 2017 to March 2020. Mr. Weaver previously served as the Chief Financial Officer from October 2015 to August 2017 with ProMetic Life Sciences, and from January to October 2015 with Oryzon Genomics. Mr. Weaver received his undergraduate degree in finance from Trinity University and his MBA from Boston College. Mr. Weaver has been selected to serve on the Company’s Board of Directors because of his qualifications as a business executive and audit committee financial expert, and his current and prior experience as a Chief Financial Officer, director and committee member of public companies. From 2014 to January 2020, Mr. Weaver served on the board of directors of Egalet Corp., a publicly traded biotech company, and from September 2014 to January 2015 on the board of directors of Oryzon Genomics, a publicly traded biotech company.

How do I contact Gregory L. Weaver?: The corporate mailing address for Mr. Weaver and other Atossa Therapeutics executives is 107 SPRING STREET, SEATTLE WA, 98104. Atossa Therapeutics can also be reached via phone at (206) 588-0256 and via email at [email protected]. Learn More on Gregory L. Weaver's contact information.
Has Gregory L. Weaver been buying or selling shares of Atossa Therapeutics?: Gregory L. Weaver has not been actively trading shares of Atossa Therapeutics during the last quarter. Most recently, Gregory L. Weaver sold 107,497 shares of the business's stock in a transaction on Friday, July 2nd. The shares were sold at an average price of $5.58, for a transaction totalling $599,833.26. Learn More on Gregory L. Weaver's trading history.
Are insiders buying or selling shares of Atossa Therapeutics?: In the last twelve months, Atossa Therapeutics insiders bought shares 1 times. They purchased a total of 25,000 shares worth more than $44,250.00. The most recent insider tranaction occured on April, 10th when Director Jonathan Finn bought 25,000 shares worth more than $44,250.00. Insiders at Atossa Therapeutics own 7.8% of the company. Learn More about insider trades at Atossa Therapeutics.
Information on this page was last updated on 4/10/2024.

Gregory L. Weaver Insider Trading History at Atossa Therapeutics

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
7/2/2021	Sell	107,497	$5.58	$599,833.26
11/21/2013	Buy	10,000	$2.58	$25,800.00

Gregory L. Weaver Buying and Selling Activity at Atossa Therapeutics

Atossa Therapeutics Company Overview

Atossa Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing medicines in the areas of unmet medical need in oncology. The company's lead program is Endoxifen, an active metabolite of tamoxifen, which is in Phase II clinical trials to treat and prevent breast cancer. It is also developing AT-H201 for lung injury caused by cancer treatment. In addition, the company develops immunotherapy/chimeric antigen receptor therapy programs. It has a research agreement with Dana-Farber Cancer Institute, Inc. to support research of cytokine-coated nanoparticles for the treatment of breast cancer. The company was formerly known as Atossa Genetics Inc. and changed its name to Atossa Therapeutics, Inc. in January 2020. Atossa Therapeutics, Inc. was founded in 2008 and is headquartered in Seattle, Washington.

Today's Range

Now: $1.53

$1.51

$1.60

50 Day Range

MA: $1.43

$0.98

$2.10

2 Week Range

Now: $1.53

$0.59

$2.31

Volume

896,406 shs

Average Volume

1,394,870 shs

Market Capitalization

$191.71 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.2

Better than Bitcoin? The Biotech Stock with 46,751% Potential

From Behind the Markets | Ad

4x Better than Bitcoin Bitcoin would have to go from $68,000 to $314,000 to match the 463% gains we saw with Immunogen in December.

Get the name of the stock here >>>